GIOTRIF® (afatinib) Dosing

GIOTRIF® (afatinib) allows for the flexibility of individualised dosing.1

The recommended starting dose for GIOTRIF® (afatinib) is 40 mg once daily.1

GIOTRIF® (afatinib) dose modification can be an important strategy to help manage adverse reactions.1 Find out more.

Dose modification has been shown to reduce the incidence of adverse drug reactions without impacting on drug effectiveness in real-world clinical practice, replicating results seen in clinical trials.1–3

Administration

GIOTRIF® (afatinib) should be taken on an empty stomach.1

  • Food should not be taken for at least three hours before and at least one hour after taking a dose

Tablets should be swallowed whole or with water.1

  • If this is not possible tablets should be dispersed until broken into small particles, for no longer than 15 minutes, in non-carbonated drinking water and consumed immediately. The glass should be rinsed with 100 ml of water which should also be swallowed

A missed dose should be taken within the same day as soon as the patient remembers.1

  • However, if the next dose is due within 8 hours then the missed dose must be skipped

 

Taking GIOTRIF® (afatinib)

Giotrif-Afatinib dosage – when to take Giotrif

Find out more about the potential side effects of treatment or learn more about monitoring and management.

References

1
GIOTRIF® (afatinib), Summary of Product Characteristics, 2018.
2
Yang JC, et al. Ann Oncol 2016;27(11):2103–2110.
3
Halmos B, et al. Lung Cancer 2018;127:103–111.

You may also be interested in...

Indication

GIOTRIF® (afatinib) in an irreversible ErbB inhibitor approved in non-small-cell lung cancer. Find out how your patients could benefit.

Learn more

AE management

Common AEs associated with GIOTRIF® (afatinib) are generally well managed with supportive care.

Learn more
Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

Read more
I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Read more
Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.